Agilent to build new facility in Colorado, increasing pharmaceutical manufacturing capacity
Expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid APIs.
Agilent Technologies has acquired 20 acres in Weld County, Colorado, on which it plans to build a pharmaceutical manufacturing facility.
The expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid APIs.
"The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases," said Skip Thune, general manager of the company's Nucleic Acids Solutions Division. "At Agilent, we are committed to meeting the ever-increasing needs of our customers for oligonucleotides."
Researchers believe oligonucleotides (short DNA and RNA molecules) hold the potential to treat various forms of cancer, diabetes, muscular dystrophy and other disorders.
Thune noted that the expansion would result in about 150 to 200 new, permanent high-paying jobs.
"Colorado is thrilled to welcome Agilent Technologies to the state," said Gov. John Hickenlooper. "This expansion will enhance Colorado's skilled workforce and dedication to research and development firms. We look forward to supporting Agilent's innovative work in our state."
"The Agilent project is a huge win for the Town of Frederick, Weld County and all of Northern Colorado," said Mike Freeman, chairman of the Weld County Commissioners. "The project adds diversification to our thriving economic base, plus significant new jobs and tax base. It also showcases what an amazing growth region Northern Colorado is due to the diverse workforce and business-friendly environment."
"The impact of new high-paying jobs and millions of dollars in investment will trigger a huge positive ripple through the local economy, pumping new revenue into everything from restaurants to housing," added Tony Carey, mayor of Frederick. "Winning this project shows the tremendous assets of Frederick and Weld County, and we welcome Agilent to our community."
"Local support paved the way for the Agilent project, and it's a great example of local governments working together to proactively accomplish a significant economic development project," said Tom Haren, chairman of the Upstate Colorado Economic Development Board.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.